MC4R — the appetite rheostat

Here the system turns inward — the same protective logic used not to shield the body from the world, but to keep it in balance with its own hunger.

Tissue

Hypothalamus & wider CNS

Key ligands

α-MSH (agonist); AgRP (inverse agonist)

Signalling

Gs → cAMP; also gates the Kir7.1 K⁺ channel independently of G-protein

Accessory protein

MRAP2 (modulatory)

Gene

18q21.32

Function

The central rheostat of appetite and body weight — and the target of the anti-obesity agent setmelanotide.

When it fails

The most common monogenic cause of severe early-onset obesity in humans.

Of the five melanocortin receptors, MC4R is the one most directly tied to a common human disease. Expressed almost entirely in the central nervous system — densely in the paraventricular nucleus (PVN) of the hypothalamus — it is the point where the brain converts a hormonal read-out of the body's energy stores into the decision to eat or to stop.^[1]

The leptin–melanocortin circuit

MC4R sits at the business end of one of the body's best-understood appetite pathways. When fat stores are full, adipose tissue releases leptin, which crosses into the brain and acts on two opposing neuron populations in the arcuate nucleus:^[2]

• POMC neurons, which leptin activates — releasing α-MSH that travels to the PVN and switches MC4R on, suppressing appetite and raising energy expenditure.
• AgRP/NPY neurons, which leptin inhibits — these release agouti-related peptide, an inverse agonist that drives MC4R activity below baseline and promotes feeding.

Appetite, in other words, is set by a tug-of-war between α-MSH and AgRP at this one receptor. Like its relatives, MC4R couples to the stimulatory G-protein Gs and signals through cyclic AMP when activated.^[1] Because the whole chain — leptin → leptin receptor → POMC → α-MSH → MC4R — is a relay, a break at any link produces a similar phenotype of relentless hunger.

When it fails: monogenic obesity

Loss-of-function mutations in MC4R cause early-onset obesity with hyperphagia, and collectively they are the most common monogenic form of obesity — reported in the order of a few percent of people with severe, childhood-onset obesity, though exact estimates vary by population and ascertainment.^[3]Mutations further upstream — in leptin (LEP), the leptin receptor (LEPR), POMC, or the processing enzyme PCSK1 — converge on the same pathway and produce overlapping syndromes.^[2] This same circuit is where the GLP-1 weight drugs act — see GLP-1 drugs and the appetite system.

Setmelanotide: refilling the signal

The therapeutic logic is direct: if the problem is too little MC4R activity, supply an agonist. Setmelanotide (marketed as Imcivree) is an MC4R agonist that works best when the receptor itself is intact but its upstream input is missing — which is why its clearest benefit is in deficiencies of POMC, PCSK1, and LEPR rather than in obesity caused by MC4R mutations themselves.^[4]

It was first approved by the FDA in November 2020 for obesity due to POMC, PCSK1, or LEPR deficiency, extended in 2022 to Bardet–Biedl syndrome, and in 2026 to acquired hypothalamic obesity.^[4] Dosing and eligibility are clinical decisions; this page describes mechanism, not treatment. See the therapeutics section for the full profile.

Beyond appetite

MC4R is not only about hunger. The same receptor contributes to energy expenditure, glucose and insulin handling, blood-pressure regulation, and erectile function — which is both why melanocortin agents have cardiovascular considerations and why the pathway is studied well beyond obesity.^[1] For how MC4R fits the wider system, see the overview pillar.

Under the hood: structure, calcium, and a second wire

For decades MC4R was understood only from the outside — by what happened when it worked or failed. Then it was finally imaged at high resolution, and the structures held two surprises that reshaped how the field thinks about it.

A calcium ion sits in the binding pocket

The first high-resolution MC4R structures revealed a calcium ion (Ca²⁺) bound in the ligand pocket itself, held jointly by the receptor and the peptide. Far from incidental, this cofactor dramatically strengthens agonist binding: extracellular calcium raises the affinity of α-MSH roughly 37-fold and its signalling potency several-hundred-fold.^[5] It also makes MC4R structurally unusual — closer to lipid-sensing receptors than to the other peptide receptors it is grouped with.^[5] Later active-state structures, captured with setmelanotide and with the natural agonist bound to its G-protein, showed exactly how the pocket closes around the ligand to switch the receptor on.^[6]

A second, G-protein-independent wire

The textbook MC4R signal is Gs → cyclic AMP. But in the appetite-controlling neurons of the paraventricular nucleus, MC4R also gates a potassium channel, Kir7.1, directly — a mechanism that needs no G-protein at all. α-MSH closes Kir7.1 to excite the neuron; strikingly, AgRP opens it, quieting the neuron independently of its ability to block α-MSH.^[7] That makes AgRP a biased agonist — the same molecule read out differently on different wires — and hints at why the receptor's pharmacology is richer than a single cAMP number can capture. The finding is important and still being worked out, so we treat it as an active area rather than settled dogma.^[7]

The MRAP2 dial

MC4R does not act entirely alone. The accessory protein MRAP2 tunes its signalling, and in humans rare loss-of-function mutations in MRAP2 cause their own form of hyperphagic obesity — often with high blood sugar and blood pressure — establishing the receptor's helper as an obesity gene in its own right.^[8] It is a reminder that the appetite circuit is a system of parts, and more than one of them can break.

← Back to all receptors

Common questions

What does the MC4R receptor do?+

MC4R is the brain’s central control of appetite and body weight: when α-MSH activates it, you feel full and energy expenditure rises. The same receptor also influences blood pressure and sexual function.

What is MC4R deficiency?+

Loss-of-function mutations in MC4R cause early-onset obesity with intense hunger (hyperphagia). Collectively they are the most common single-gene (monogenic) cause of severe obesity in humans.

Can MC4R be targeted for weight loss?+

Yes. The MC4R agonist setmelanotide is approved for certain rare genetic and acquired hypothalamic obesity. Conversely, blocking MC4R is being studied to treat wasting (cachexia) — the same receptor, used in opposite directions.

References

1. 1.Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 27(7):736–49. 2006. link ↗
2. 2.Fansa S, Acosta A. The melanocortin-4 receptor pathway and the emergence of precision medicine in obesity management. Review (PMC11893075). 2024. link ↗
3. 3.Collet T-H, et al. Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab. 103(7):2601–12. 2018. link ↗
4. 4.StatPearls. Setmelanotide. NCBI Bookshelf (NBK589641). 2024. link ↗
5. 5.Yu J, Gimenez LE, Hernandez CC, et al. Determination of the melanocortin-4 receptor structure identifies Ca²⁺ as a cofactor for ligand binding. Science. 368(6489):428–33. 2020. link ↗
6. 6.Israeli H, Degtjarik O, Fierro F, et al. Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling. Science. 372(6544):808–14. 2021. link ↗
7. 7.Ghamari-Langroudi M, Digby GJ, Sebag JA, et al. G-protein-independent coupling of MC4R to Kir7.1 in hypothalamic neurons. Nature. 520(7545):94–8. 2015. link ↗
8. 8.Baron M, Maillet J, Huyvaert M, et al. Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension. Nat Med. 25(11):1733–8. 2019. link ↗